165 related articles for article (PubMed ID: 24481293)
1. Precompetitive activity to address the biological data needs of drug discovery.
Sidders B; Brockel C; Gutteridge A; Harland L; Jansen PG; McEwen R; Michalovich D; Seidel H; Weiss B; Williams-Jones B; Woodwark M
Nat Rev Drug Discov; 2014 Feb; 13(2):83-4. PubMed ID: 24481293
[No Abstract] [Full Text] [Related]
2. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
Perakslis ED; Van Dam J; Szalma S
Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
[No Abstract] [Full Text] [Related]
3. Precompetitive research: a new prescription for drug development?
Woodcock J
Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454
[No Abstract] [Full Text] [Related]
4. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
Woosley RL; Myers RT; Goodsaid F
Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
[TBL] [Abstract][Full Text] [Related]
5. Precompetitive consortia in biomedicine--how are we doing?
Mittleman B; Neil G; Cutcher-Gershenfeld J
Nat Biotechnol; 2013 Nov; 31(11):979-85. PubMed ID: 24213770
[No Abstract] [Full Text] [Related]
6. Arguments against precompetitive collaboration.
Vargas G; Boutouyrie B; Ostrowitzki S; Santarelli L
Clin Pharmacol Ther; 2010 May; 87(5):527-9. PubMed ID: 20407456
[No Abstract] [Full Text] [Related]
7. Market watch: Biopharma deal-making in 2014: a record year for M&A value.
Micklus A; Muntner S
Nat Rev Drug Discov; 2015 Feb; 14(2):84-5. PubMed ID: 25633786
[No Abstract] [Full Text] [Related]
8. Open access chemical and clinical probes to support drug discovery.
Edwards AM; Bountra C; Kerr DJ; Willson TM
Nat Chem Biol; 2009 Jul; 5(7):436-40. PubMed ID: 19536100
[TBL] [Abstract][Full Text] [Related]
9. Novelty in the target landscape of the pharmaceutical industry.
Agarwal P; Sanseau P; Cardon LR
Nat Rev Drug Discov; 2013 Aug; 12(8):575-6. PubMed ID: 23903214
[No Abstract] [Full Text] [Related]
10. Open-minded to open innovation and precompetitive collaboration.
Wagner JA
Clin Pharmacol Ther; 2010 May; 87(5):511-5. PubMed ID: 20407451
[No Abstract] [Full Text] [Related]
11. The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.
Wagner JA; Prince M; Wright EC; Ennis MM; Kochan J; Nunez DJ; Schneider B; Wang MD; Chen Y; Ghosh S; Musser BJ; Vassileva MT
Clin Pharmacol Ther; 2010 May; 87(5):539-42. PubMed ID: 20407460
[TBL] [Abstract][Full Text] [Related]
12. Europe fiddles while innovation burns.
Frantz S
Nat Rev Drug Discov; 2005 Sep; 4(9):704-5. PubMed ID: 16178115
[No Abstract] [Full Text] [Related]
13. Tropical disease: A neglected cause.
Laursen L
Nature; 2016 May; 533(7602):S68-9. PubMed ID: 27167396
[No Abstract] [Full Text] [Related]
14. David Haslam. Interview by Asher Mullard.
Haslam D
Nat Rev Drug Discov; 2013 Jul; 12(7):500. PubMed ID: 23764976
[No Abstract] [Full Text] [Related]
15. Patent-free pact pushes the boundaries of precompetitive research.
Dolgin E
Nat Med; 2014 Jun; 20(6):564-5. PubMed ID: 24901552
[No Abstract] [Full Text] [Related]
16. Competition: Unlikely partnerships.
Savage N
Nature; 2016 May; 533(7602):S56-8. PubMed ID: 27167391
[No Abstract] [Full Text] [Related]
17. Traditional drug-discovery model ripe for reform.
Cressey D
Nature; 2011 Mar; 471(7336):17-8. PubMed ID: 21368796
[No Abstract] [Full Text] [Related]
18. Showcasing bioscience in Rhode Island.
Spero D
R I Med J (2013); 2013 Feb; 96(2):15. PubMed ID: 23641419
[TBL] [Abstract][Full Text] [Related]
19. Q&A: Bernard Munos.
Bender E
Nature; 2016 May; 533(7602):S59. PubMed ID: 27167392
[No Abstract] [Full Text] [Related]
20. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
Hedner T; Gatenbeck L
Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
[No Abstract] [Full Text] [Related]
[Next] [New Search]
